pravastatin has been researched along with aspirin in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (7.84) | 18.2507 |
| 2000's | 25 (49.02) | 29.6817 |
| 2010's | 18 (35.29) | 24.3611 |
| 2020's | 4 (7.84) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Verheugt, FW | 1 |
| Ambrose, JA; Badimon, JJ; Dangas, G; Fallon, JT; Fier, C; Levine, D; Meraj, P; Shao, JH; Smith, DA; Unger, AH | 1 |
| Bloom, JM | 1 |
| Davis, KB; Egan, DA; Garg, R; Griffin, B; Pettinger, MB; Thomason, T; Waclawiw, MA | 1 |
| Bero, L; Henry, D; Lee, K; Mah, C; Moynihan, R; Ross-Degnan, D; Soumerai, SB; Watkins, J | 1 |
| Roberts, CS | 1 |
| Applegate, WB; Crouse, JR; Davis, KB; Egan, D; Elam, MB; Garg, R; Herd, JA; Hunninghake, DB; Johnson, WC; Kennedy, JW; Kostis, JB; Sheps, DS | 1 |
| Rifai, N; Yu, H | 1 |
| Guijarro, C | 1 |
| Armstrong, PW; Borer, J; Lorell, BH; Nissen, S | 1 |
| Baiano, A; de Cristofaro, A; Del Forno, D; Giallauria, F; Paragliola, T; Rossi, M; Vigorito, C | 1 |
| Diener, HC | 1 |
| Belder, R; Berry, DA; Berry, SM; Byington, RP; Fiedorek, FT; Ford, NF; Hennekens, CH; Jukema, JW; Natarajan, K; Pitt, B; Sacks, FM; Sheng-Lin, C; Tonkin, A; Walker, AJ | 1 |
| Ruef, J | 1 |
| Fang, CH; Li, JJ | 1 |
| Curtiss, FR | 1 |
| Bermas, B; Costenbader, KH; de Pablo, P; Finckh, A; Gall, V; Karlson, EW; Liang, MH; Lynch, M; Schur, PH | 1 |
| Cooper, AJ; Dusse, LM; Lwaleed, BA | 1 |
| Billinger, M; Cook, S; Haeberli, A; Hess, OM; Meier, B; Togni, M; Wenaweser, P; Windecker, S | 1 |
| Cawich, I; Chen, J; Dandapat, A; Deonikar, P; Hu, CP; Kavdia, M; Marwali, MR; Mehta, JL; Mohandas, B; Sawamura, T | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Xiao, H; Yang, CS | 1 |
| Hennekens, C | 1 |
| Berk, M; Henry, MJ; Jacka, FN; Kotowicz, MA; Nicholson, GC; Pasco, JA; Williams, LJ | 1 |
| Chen, JW; Tan, ZM; Zhou, SB | 1 |
| Luzak, B; Rywaniak, J; Stanczyk, L; Watala, C | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| Latorre, A; Madrid, I; Moscardó, A; Santos, MT; Vallés, J | 1 |
| Alexander, MR; Burley, JC; Khaled, SA; Roberts, CJ; Yang, J | 1 |
| Costantine, MM | 1 |
| Costantine, MM; Marrs, CC | 1 |
| Ahn, CM; Cheong, SS; Cho, DK; Cho, YH; Choi, D; Her, AY; Hong, MK; Im, E; Jang, Y; Kang, WC; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Lee, K; Shin, DH; Suh, Y; Yoo, SY; Yun, KH | 1 |
| Burns, RB; Graham, K; Reynolds, EE; Sawhney, MS | 1 |
| Andriessen, VC; Connell, MT; Flannagan, KS; Hill, MJ; Mumford, SL; Perkins, NJ; Plowden, TC; Radoc, JG; Schisterman, EF; Sjaarda, LA; Zolton, JR | 1 |
| Contento, G; Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J; Varoudi, K | 1 |
| Asher-Landsberg, J; Gamzu, R; Kliger, C; Kupferminc, MJ; Rimon, E; Skornick-Rapaport, A; Yogev, Y | 1 |
| Costantine, MM; Eid, J; Rood, KM | 1 |
| Cassola, N; Clezar, CN; Flumignan, CD; Flumignan, RL; Nakano, LC; Trevisani, VF | 1 |
8 review(s) available for pravastatin and aspirin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Topics: Aged; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2004 |
[Interactions of statins with antithrombotic drugs].
Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Controlled Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Primary Prevention; Pyrroles; Rats; Ticlopidine; Time Factors | 2004 |
Tissue factor and nitric oxide: a controversial relationship!
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitrates; Nitric Oxide; Pravastatin; Thromboplastin; Up-Regulation | 2007 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes].
Topics: Aspirin; Atherosclerosis; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2007 |
Aspirin and Pravastatin for Preeclampsia Prevention in High-Risk Pregnancy.
Topics: Aspirin; Female; Humans; Hypertension; Infant, Newborn; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy, High-Risk | 2023 |
Pharmacological interventions for asymptomatic carotid stenosis.
Topics: Aspirin; Atherosclerosis; Atorvastatin; Carotid Stenosis; Chlorthalidone; Fluvastatin; Hemorrhage; Humans; Ischemic Stroke; Metoprolol; Pravastatin; Probucol; Rosuvastatin Calcium; Stroke; Warfarin | 2023 |
8 trial(s) available for pravastatin and aspirin
| Article | Year |
|---|---|
Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.
Topics: Aged; Aspirin; Blood Coagulation Factors; Cholesterol, LDL; Coronary Thrombosis; Double-Blind Method; Female; Fibrinolytic Agents; Follow-Up Studies; Hemostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoprotein(a); Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 1999 |
Compliance to multiple interventions in a high risk population.
Topics: Adult; Aged; Anticholesteremic Agents; Anticoagulants; Antioxidants; Aspirin; Data Interpretation, Statistical; Double-Blind Method; Female; Humans; Male; Niacin; Patient Compliance; Peripheral Vascular Diseases; Placebos; Platelet Aggregation Inhibitors; Pravastatin; Time Factors; Warfarin | 1999 |
Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Antioxidants; Arteriosclerosis; Aspirin; Cholesterol, LDL; Feasibility Studies; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Niacin; Platelet Aggregation Inhibitors; Pravastatin; Risk Factors; Self Medication; Time Factors; Treatment Outcome; Triglycerides; Vitamins; Warfarin | 2000 |
Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Aspirin; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Patient Dropouts; Patient Selection; Pilot Projects; Pravastatin; Ramipril; Treatment Refusal; Vitamin B Complex | 2005 |
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Prosthesis Failure; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2007 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pravastatin; Stroke; Treatment Outcome | 2018 |
Pilot randomized trial of short-term changes in inflammation and lipid levels during and after aspirin and pravastatin therapy.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Female; Humans; Inflammation; Lipids; Pilot Projects; Pravastatin; Treatment Outcome; Young Adult | 2019 |
35 other study(ies) available for pravastatin and aspirin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Aspirin, the poor man's statin?
Topics: Anticoagulants; Aspirin; Female; Humans; Lovastatin; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Risk Factors; Warfarin | 1998 |
Pravastatin and coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin | 1999 |
Coverage by the news media of the benefits and risks of medications.
Topics: Alendronate; Anticholesteremic Agents; Aspirin; Biomedical Research; Cardiovascular Diseases; Conflict of Interest; Cost-Benefit Analysis; Disclosure; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fees, Pharmaceutical; Humans; Journalism, Medical; Mass Media; Newspapers as Topic; Osteoporosis; Pravastatin; Risk Assessment; Television; United States | 2000 |
Postoperative drug therapy to extend survival after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Female; Humans; Male; Postoperative Care; Pravastatin; Survival Rate | 2000 |
High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Risk Factors | 2000 |
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pravastatin; Predictive Value of Tests; Risk Assessment; Sensitivity and Specificity | 2001 |
Pravastatin and Aspirin.
Topics: Advisory Committees; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Packaging; Drug Therapy, Combination; Humans; Hypertension; Pravastatin | 2002 |
[Cardiac rehabilitation in a HIV-patient treated with protease inhibitors].
Topics: Adult; Aspirin; Carbazoles; Carvedilol; Cholesterol; Coronary Angiography; Diet Therapy; Drug Therapy, Combination; Enalapril; Exercise Therapy; HIV Infections; Humans; Male; Myocardial Infarction; Nitrates; Pravastatin; Propanolamines; Protease Inhibitors; Treatment Outcome; Triglycerides | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke | 2003 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles | 2005 |
Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Drug Therapy, Combination; Fibrinogen; Humans; Integrin alpha2beta1; Nitric Oxide; Oxidative Stress; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Pravastatin; Scavenger Receptors, Class E; Signal Transduction | 2007 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression.
Topics: Aspirin; Atorvastatin; Case-Control Studies; Confidence Intervals; Cytokines; Depressive Disorder, Major; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Middle Aged; Models, Psychological; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2010 |
Aspirin and pravastatin reduce lectin-like oxidized low density lipoprotein receptor-1 expression, adhesion molecules and oxidative stress in human coronary artery endothelial cells.
Topics: Anticholesteremic Agents; Aspirin; Blotting, Western; Cell Adhesion Molecules; Cells, Cultured; Coronary Vessels; Cyclooxygenase Inhibitors; Electrophoretic Mobility Shift Assay; Endothelial Cells; Humans; Oxidative Stress; Pravastatin; Scavenger Receptors, Class E; Superoxides | 2010 |
Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition.
Topics: Adult; Aspirin; Atorvastatin; Blood Platelets; Cholesterol; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Young Adult | 2012 |
Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Blood Platelets; Calcium; Collagen; Cyclooxygenase 1; Drug Combinations; Drug Synergism; Heptanoic Acids; Humans; Mitogen-Activated Protein Kinases; Phospholipase A2 Inhibitors; Phospholipases A2; Phosphorylation; Platelet Aggregation; Pravastatin; Pyrroles; Simvastatin; Thromboxane A2; Thromboxane-A Synthase | 2013 |
3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles.
Topics: Aspirin; Atenolol; Delayed-Action Preparations; Drug Combinations; Drug Liberation; Excipients; Hydrochlorothiazide; Powder Diffraction; Pravastatin; Printing, Three-Dimensional; Ramipril; Solubility; Spectroscopy, Fourier Transform Infrared; Tablets; X-Ray Diffraction | 2015 |
Pravastatin to prevent obstetrical complications in women with antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Aspirin; Female; Humans; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy Complications | 2016 |
Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Pravastatin; Pre-Eclampsia; Pregnancy; Risk Factors | 2017 |
Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Topics: Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Primary Prevention; Risk Assessment | 2017 |
Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fetal Growth Retardation; Hemodynamics; Heparin, Low-Molecular-Weight; Humans; Mice; Mice, Inbred C57BL; Nitric Oxide; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2020 |
Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study.
Topics: Abruptio Placentae; Aspirin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans; Pilot Projects; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Retrospective Studies; Stillbirth | 2022 |